| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) does not have a defined biological target as it is primarily a synthetic building block and research chemical for proteomics studies rather than a therapeutic agent. The compound is used as a chemical scaffold or intermediate for the synthesis of more complex biologically active molecules. The pyrrole core is a common heterocycle found in many natural products and pharmaceuticals, and the formyl and ester groups allow for diverse chemical transformations. However, the parent compound itself is not known to bind to any specific protein or receptor. Its primary role is as a research chemical in proteomics and medicinal chemistry, serving as a precursor for the construction of compound libraries or for the synthesis of molecules with defined biological targets.
|
|---|---|
| ln Vitro |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without documented direct biological activity. The compound is classified as a biochemical assay reagent and a research chemical for proteomics. No IC50, EC50, or other potency values have been reported for this substance in the context of target-based assays. Its primary role is in chemical synthesis for preparing more complex molecules, not as a pharmacologically active agent itself. The compound may be used to create compound libraries that are subsequently screened for biological activity.
|
| ln Vivo |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without documented in vivo biological activity. The compound is intended for chemical synthesis and proteomics research rather than pharmacological evaluation in animal models. It does not possess intrinsic therapeutic properties as a standalone agent. Any in vivo activity would be associated with the final compounds synthesized from this building block, not with the precursor itself. The compound is not typically administered to animals for efficacy studies.
|
| Enzyme Assay |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without reported receptor binding properties. For general organic chemistry applications, no protein or receptor binding assays have been reported. The compound‘s functional groups (formyl, ester, pyrrole NH) make it suitable for various chemical transformations, but these are not biological binding assays. Standard analytical characterization for this compound includes NMR spectroscopy, GC/HPLC analysis for purity determination (>95-97% by GC/HPLC), and mass spectrometry. These methods are used for quality control and chemical identification, not for biological binding assessments.
|
| Cell Assay |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without documented cell-based activity. This compound is not typically used in cell culture experiments as a pharmacologically active agent. Its primary applications are in organic synthesis as a starting material for drug manufacturing and as a research chemical in proteomics. Standard practice involves converting this building block into final test compounds before biological testing. No direct cell-based assays for the parent compound are reported in the available literature. It is considered a chemical intermediate or research chemical, not a test article for cell-based efficacy assays. However, as a proteomics research chemical, it may be used to chemically modify proteins or peptides for mass spectrometry applications, but this is not a cell-based activity assay.
|
| Animal Protocol |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without documented in vivo animal study protocols. The compound is used as a chemical precursor rather than as a test article for animal efficacy studies. Any animal studies involving this compound would be for toxicological safety assessment of the chemical itself, not for therapeutic efficacy evaluation. Standard OECD guidelines for chemical safety testing could apply, but no specific protocols are reported in the available literature for this compound. The compound is typically further transformed into more complex molecules before animal studies. As a proteomics research chemical, it may be used in ex vivo protein labeling studies, but these are not in vivo animal efficacy studies.
|
| ADME/Pharmacokinetics |
Not applicable for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) as it is a synthetic building block without reported pharmacokinetic studies. The compound is not intended for systemic drug delivery. For chemical safety assessment, the compound has predicted physicochemical properties including moderate lipophilicity (estimated logP ~1.5), one hydrogen bond donor (pyrrole NH), three hydrogen bond acceptors (formyl O, ester O, and ester O), and three rotatable bonds. No formal PK data in humans or animals have been reported. The compound is used primarily as a research chemical in proteomics and medicinal chemistry, not as a pharmaceutical candidate requiring PK characterization.
|
| Toxicity/Toxicokinetics |
Toxicity data for Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) are not widely reported in the available literature. The compound is intended for research use only and not for human therapeutic applications. Standard safety precautions for handling include: avoid dust formation, use appropriate personal protective equipment (chemical-resistant gloves, safety goggles, lab coat), ensure adequate ventilation (use fume hood), avoid contact with skin, eyes, and clothing, and avoid inhalation of dust or vapors. The compound may cause skin and eye irritation. In case of accidental ingestion, seek medical attention. Storage: in a cool, dry, well-ventilated area in a tightly sealed container, protected from light and moisture. No specific acute toxicity values (LD50) are reported in the available literature. The compound should be handled with care, and users should consult the Safety Data Sheet for comprehensive safety information.
|
| References | |
| Additional Infomation |
Ethyl 4-formyl-1H-pyrrole-2-carboxylate (7126-57-0) has a molecular formula of C8H9NO3 and molecular weight of 167.16 g/mol. Its IUPAC name is ethyl 4-formyl-1H-pyrrole-2-carboxylate. Synonyms include 4-formyl-1H-pyrrole-2-carboxylic acid ethyl ester, ethyl 4-formylpyrrole-2-carboxylate, NSC272668, and AKY-A0602-0894. The compound appears as a solid (crystals or powder) at room temperature. Melting point: 100-105degC. Purity: typically >95% by HPLC/GC (97% standard purity). Storage conditions: store in a cool, dry, well-ventilated area in a tightly closed container, protected from light and moisture. The compound contains a secondary amine (pyrrole NH) and is stable under recommended storage conditions. Applications: used in proteomics research and as a synthetic building block for medicinal chemistry. The compound is available as a solid in small quantities (milligram to gram scale).
|
| Molecular Formula |
C8H9NO3
|
|---|---|
| Molecular Weight |
167.16
|
| Exact Mass |
167.058
|
| CAS # |
7126-57-0
|
| PubChem CID |
321486
|
| Appearance |
Light yellow to light brown solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
12
|
| Complexity |
181
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)C1=CC(=CN1)C=O
|
| InChi Key |
WVSAWXIWWNJTAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H9NO3/c1-2-12-8(11)7-3-6(5-10)4-9-7/h3-5,9H,2H2,1H3
|
| Chemical Name |
ethyl 4-formyl-1H-pyrrole-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL | |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL | |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
